I bought this because they are trying to do a partnering deal for the upcoming trial. DAAs are far too expensive and so is the final bill for any trial so it made great sense. This was pointed out in the prospectus.
It may not dilute the register but it will dilute. I don't expect any trial deal to be done until after the SVR12 results are out for the G3 cohort in Thailand. That will be six months after the 2Q RVR results are out. Which means NOVEMBER. More money will be required before that date I think.
